Carregant...

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis

Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing–remitting multip...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Brown, JWL, Coles, Alasdair J
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2013
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3593763/
https://ncbi.nlm.nih.gov/pubmed/23494602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S32687
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!